Share on StockTwits

CRT Capital hoisted their target price on shares of Edwards Lifesciences Corp (NYSE:EW) from $90.00 to $100.00 in a research note issued on Thursday. CRT Capital’s price objective would indicate a potential upside of 8.73% from the stock’s previous close.

In other Edwards Lifesciences Corp news, VP Patrick B. Verguet sold 5,000 shares of Edwards Lifesciences Corp stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $92.00, for a total value of $460,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

A number of other firms have also recently commented on EW. Analysts at BMO Capital Markets raised their price target on shares of Edwards Lifesciences Corp from $84.00 to $89.00 in a research note on Thursday. Separately, analysts at Deutsche Bank reiterated a “hold” rating on shares of Edwards Lifesciences Corp in a research note on Wednesday. They now have a $90.00 price target on the stock, up previously from $81.00. Finally, analysts at Barclays reiterated an “equal weight” rating on shares of Edwards Lifesciences Corp in a research note on Wednesday. They now have a $73.00 price target on the stock, up previously from $67.00. Six analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $90.00.

Shares of Edwards Lifesciences Corp (NYSE:EW) traded up 1.91% on Thursday, hitting $91.97. 1,899,876 shares of the company’s stock traded hands. Edwards Lifesciences Corp has a 1-year low of $60.62 and a 1-year high of $94.50. The stock’s 50-day moving average is $85.98 and its 200-day moving average is $77.78. The company has a market cap of $9.712 billion and a P/E ratio of 13.02.

Edwards Lifesciences Corp (NYSE:EW) last announced its earnings results on Tuesday, July 29th. The company reported $0.88 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the prior year, the company posted $0.82 earnings per share. The company’s quarterly revenue was up 11.2% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp will post $3.28 earnings per share for the current fiscal year.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.